Domain | Product | Indication | Pre-clinical | Phase I | Phase II | Phase III | NDA | Marketed | |
---|---|---|---|---|---|---|---|---|---|
Pulmonary Diseases
|
Fibrosis-associated
|
ETUARY® (Pirfenidone) |
Idiopathic Pulmonary Fibrosis(IPF)
|
|
|||||
Pulmonary Diseases
|
Fibrosis-associated
|
ETUARY® (Pirfenidone) |
Dermatomyositis Interstitial Lung disease (DM-ILD)
|
|
|||||
Pulmonary Diseases
|
Fibrosis-associated
|
ETUARY® (Pirfenidone) |
Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
|
|
|||||
Pulmonary Diseases
|
Fibrosis-associated
|
ETUARY® (Pirfenidone) |
Pneumoconiosis |
|
|||||
Pulmonary Diseases
|
Others
|
F528(Novel Anti-inflammatory Small Molecule Drug) | Chronic Obstructive Pulmonary Disease(COPD) |
|
|||||
Pulmonary Diseases
|
Others
|
F230(Selective endothelin receptor antagonist) |
Pulmonary Arterial Hypertension (PAH)
|
|
|||||
Liver Diseases
|
Fibrosis
|
F351 (Hydronidone) | Chronic Hepatitis B Liver Fibrosis |
|
|||||
Liver Diseases
|
Other
|
F573(Caspase protease inhibitor) |
Acute Liver Failure
(ALF) / Acute-on-Chronic Liver Failure (ACLF) |
|
|||||
Kidney Disease
|
Fibrosis Associated
|
ETUARY® (Pirfenidone) |
Diabetic Kidney Disease (DKD) |
|